Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a treatment called ADI-PEG 20 combined with standard chemotherapy (pemetrexed and platinum), compared to a placebo (an inactive substitute) plus the same standard chemotherapy. The trial ran in two stages — a Phase 2 portion (87 people in the ADI-PEG 20 group and 89 in the placebo group) and a Phase 3 portion (125 and 124 people respectively). The main things being measured were how many participants' tumours shrank or disappeared (called the "response rate"), and how long participants lived overall ("overall survival"). A secondary measure tracked how long participants went before their disease got worse ("progression-free survival"). The reported data shows that in the response rate measurement, 12 participants in each group had their tumours shrink or disappear. For overall survival, the trial reported a median of approximately 9.30 months in the ADI-PEG 20 group compared to 7.66 months in the placebo group at the final analysis. An earlier mid-trial check reported figures of 9.82 months versus 7.49 months respectively. (Median here simply means the point at which half the participants in each group had passed away and half were still living.) For progression-free survival — the time before the disease got worse — the reported median was 6.24 months in the ADI-PEG 20 group and 5.65 months in the placebo group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 38358753) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Mesothelioma Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been confirmed by a tissue biopsy to have a type of mesothelioma (a cancer affecting the lining of the lungs) that cannot be removed by surgery, and it is either the "biphasic" or "sarcomatoid" type
- You have not yet received any chemotherapy or immunotherapy treatment for this cancer
- You are generally well enough to carry out light activity and care for yourself (a doctor will assess your overall fitness level)
- Your doctors expect you to live for at least 3 more months
- You are 18 years of age or older (there is no upper age limit)
- Your cancer can be measured using standard imaging scans
- You are willing and able to give written consent and can take part in the treatment and follow-up appointments
- Your blood tests show that your blood, liver, and kidneys are working well enough to take part
Who may not be able to join:
- You have had radiotherapy (other than for pain relief) within the last two weeks before starting the study treatment
- You have a history of an unstable heart condition
- You are still experiencing significant side effects from a previous cancer treatment
- You have cancer that has spread to your brain or spinal cord and is causing symptoms, unless it has been stable for more than one month after treatment
- You have recently had major surgery on your chest or abdomen and have not yet fully recovered
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: John S Bomalaski, MD, Polaris Group
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Response Rate; Overall Survival Phase 3 Interim Analysis; Overall Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.